Treatment-associated decline in JAK2V617F allele burden in polycythemia vera: What does it mean?

被引：2
|
作者：
Tefferi, Ayalew [1 ]
Pardanani, Animesh [1 ]
Gangat, Naseema [1 ]
机构：
[1] Mayo Clin, Dept Med, Div Hematol, 200 First St SW, Rochester, MN 55905 USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 08期
关键词：
HYDROXYUREA; MUTATIONS; THERAPY; CALRETICULIN; RUXOLITINIB; JAK2(V617F); TRIAL; AGE;
D O I：
10.1002/ajh.27375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1459 / 1461
页数：3
相关论文
共 50 条
  • [31] Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden
    Larsen, Thomas Stauffer
    Pallisgaard, Niels
    de Stricker, Karin
    Moller, Michael Boe
    Hasselbalch, Hans Carl
    HEMATOLOGY, 2009, 14 (01) : 11 - 15
  • [32] Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib
    Pacilli, Annalisa
    Fanelli, Tiziana
    Mannarelli, Carmela
    Rotunno, Giada
    Pancrazzi, Alessandro
    Vannucchi, Alessandro Maria
    Guglielmelli, Paola
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 357 - 359
  • [33] Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients
    Spanoudakis, Emmanouil
    Bazdiara, Ioanna
    Kotsianidis, Ioannis
    Margaritis, Dimitrios
    Goutzouvelidis, Aggelos
    Christoforidou, Anna
    Tsatalas, Costas
    Bourikas, George
    ANNALS OF HEMATOLOGY, 2009, 88 (07) : 629 - 632
  • [34] Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients
    Emmanouil Spanoudakis
    Ioanna Bazdiara
    Ioannis Kotsianidis
    Dimitrios Margaritis
    Aggelos Goutzouvelidis
    Anna Christoforidou
    Costas Tsatalas
    George Bourikas
    Annals of Hematology, 2009, 88 : 629 - 632
  • [35] JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
    Tefferi, Ayalew
    Lavu, Sravanthi
    Mudireddy, Mythri
    Lasho, Terra L.
    Finke, Christy M.
    Gangat, Naseema
    Pardanani, Animesh
    Hanson, Curtis A.
    Mannarelli, Carmela
    Guglielmelli, Paola
    Vannucchi, Alessandro M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (04) : E93 - E96
  • [36] Clonal hematopoiesis and cardiovascular diseases: role of JAK2V617F
    Misaka, Tomofumi
    Kimishima, Yusuke
    Yokokawa, Tetsuro
    Ikeda, Kazuhiko
    Takeishi, Yasuchika
    JOURNAL OF CARDIOLOGY, 2023, 81 (01) : 3 - 9
  • [37] Endothelial Damage in JAK2V617F Myeloproliferative Neoplasms with Splanchnic Vein Thrombosis
    De Moner, Blanca
    Martinez-Sanchez, Julia
    Garrote, Marta
    Ramos, Alex
    Ventosa-Capell, Helena
    Moreno-Castano, Ana
    Nomdedeu, Meritxell
    Ojeda, Asuncion
    Escolar, Gines
    Garcia-Pagan, Joan Carles
    Arellano-Rodrigo, Eduardo
    Carreras, Enric
    Alvarez-Larran, Alberto
    Diaz-Ricart, Maribel
    THROMBOSIS AND HAEMOSTASIS, 2025,
  • [38] TET2 loss, a rescue of JAK2V617F HSCs
    Vainchenker, William
    Plo, Isabelle
    BLOOD, 2015, 125 (02) : 212 - 213
  • [39] Relation of JAK2 V617F allele burden and coronary calcium score in patients with essential thrombocythemia
    Drofenik, Ajda
    Blinc, Ales
    Mijovski, Mojca Bozic
    Pajic, Tadej
    Vrtovec, Matjaz
    Sever, Matjaz
    RADIOLOGY AND ONCOLOGY, 2024, 58 (04) : 565 - 572
  • [40] Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F
    Stein, Brady L.
    Oh, Stephen T.
    Berenzon, Dmitriy
    Hobbs, Gabriela S.
    Kremyanskaya, Marina
    Rampal, Raajit K.
    Abboud, Camille N.
    Adler, Kenneth
    Heaney, Mark L.
    Jabbour, Elias J.
    Komrokji, Rami S.
    Moliterno, Alison R.
    Ritchie, Ellen K.
    Rice, Lawrence
    Mascarenhas, John
    Hoffman, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (33) : 3953 - +
12345